Figures & data
Table 1 Main Dysregulated miRNAs in Serum from Patients with COPD vs. Smokers Without the Disease at Baseline
Figure 1 Heat Map showing the expression profiling of circulating miRNAs in patients with COPD and control smokers without COPD. miRNA assay by NGS was performed in 14 serum samples (7 corresponds to baseline (named COPD-1 to 4_bas and Controls-1 to 3_bas) and 7 to the sample individuals after 10 years of follow-up (named COPD-1 to 4_10y and Controls-1 to 3_10y)). Red represents a high level of gene expression while green represents a low level of expression.
Figure 2 Volcano plot showing differentially expressed miRNAs in terms of the fold change in normalized expression in COPD patients at baseline compared to COPD patients after 10 years follow-up. The 10 microRNAs with the lowest p-values are marked with names on the plot (p-values <0.02 and log fold change (LogFC) >1).
Table 2 Baseline Clinical and Lung Function Characteristics of the COPD Patients and Control Smokers Included in the Validation Study
Table 3 Baseline and 10-Years Follow-Up Clinical and Lung Function Characteristics of the COPD Patients Included in the Validation Study
Figure 3 Dysregulated expression of miR-1246 in COPD patients with emphysema (A) and patients without emphysema (B) at 10 years-follow-up in contrast to baseline.
Table 4 The Enriched KEGG Pathway of Predicted Genes